

**15 -ാം കേരള നിയമസഭ**

**11 -ാം സമ്മേളനം**

**നക്ഷത്ര ചിഹ്നം ഇല്ലാത്ത ചോദ്യം നം. 4093**

**28-06-2024 - ൽ മറുപടിയ്ക്ക്**

**കെ.എം.എസ്.സി.എൽ.-ൽ ബ്ലീച്ചിങ് പൗഡർ ടെൻഡർ ഇല്ലാതെ വാങ്ങിയ നടപടി**

ചോദ്യം		ഉത്തരം	
ശ്രീ. സജീവ് ജോസഫ്		ശ്രീമതി വീണാ ജോർജ്ജ് (ആരോഗ്യ- വനിത-ശിശുവികസന വകുപ്പ് മന്ത്രി)	
(എ)	2022-2023 സാമ്പത്തിക വർഷത്തിൽ കെ.എം.എസ്.സി.എൽ.-ൽ ബ്ലീച്ചിങ് പൗഡർ ടെൻഡർ മുഖേന വാങ്ങിയിട്ടുണ്ടോ; ഈ കാലയളവിൽ ടെൻഡർ മുഖേന അല്ലാതെ ബ്ലീച്ചിങ് പൗഡർ വാങ്ങിയതിന്റെ മാനദണ്ഡം വ്യക്തമാക്കുമോ; പ്രസ്തുത നടപടി രേഖകളുടെ പകർപ്പ് ലഭ്യമാക്കാമോ;	(എ)	<p>കേരള മെഡിക്കൽ സർവീസസ് കോർപ്പറേഷൻ 2022-23-ൽ ടെണ്ടർ മുഖേന ബ്ലീച്ചിംഗ് പൗഡർ വാങ്ങിയിട്ടില്ല.</p> <p>2022-23 സാമ്പത്തിക വർഷത്തിൽ ബ്ലീച്ചിങ് പൗഡറിന്റെ സംഭരണത്തിനും വിതരണത്തിനുമായി കോർപ്പറേഷൻ 04.12.2021ന് ടെൻഡർ വിളിച്ചിരുന്നെങ്കിലും വിതരണക്കാരെ ലഭ്യമാക്കാത്തതിനാൽ റീ ടെൻഡർ വിളിക്കുകയും അതിലും വിതരണക്കാരെ ലഭ്യമാക്കാത്ത സാഹചര്യത്തിൽ ബ്ലീച്ചിങ് പൗഡർ 30% 1 K.G പാക്കറ്റ് കാരുണ്യ കമ്മ്യൂണിറ്റി വിഭാഗം വഴി സംഭരിക്കാൻ 10.05.2022 ലെ ഡയറക്ടർ ബോർഡ് തീരുമാനിച്ചതിന്റെ അടിസ്ഥാനത്തിൽ 2022-2023 സാമ്പത്തിക വർഷത്തിൽ 9,85,370 യൂണിറ്റ് സംഭരിക്കാൻ അവശ്യ മരുന്ന് വിഭാഗം കാരുണ്യ കമ്മ്യൂണിറ്റി ഫർമസിക്ക് 4 വിതരണോത്തരവുകൾ നൽകിയിരുന്നു.</p> <p>വിലപേശൽ പ്രക്രിയയിലൂടെയാണ് (NEGOTIATION PROCESS) വില നിശ്ചയിച്ചത്. ഇതിൻ പ്രകാരം കാരുണ്യ കമ്മ്യൂണിറ്റി വിഭാഗം 09/06/2022 ലെ KMSCL/KCP/Q4/2022-2023 നമ്പരായ online sealed Quotation പ്രകാരം ബ്ലീച്ചിങ് പൗഡർ ഉൾപ്പെടെ 17 ഇനങ്ങൾക്ക് ക്വട്ടേഷൻ ക്ഷണിച്ചു.</p> <p>പ്രസ്തുത ഇനത്തിന് രണ്ടു വിതരണക്കാർക്ക് ഏറ്റവും കുറഞ്ഞ നിരക്കിൽ 30.07.2022 ൽ ബാങ്കെ ബിഹാരി, പാർകിൻസ് എന്റർപ്രൈസസ് എന്നീ കമ്പനികൾക്ക് 47.08/- രൂപ നിരക്കിൽ വിതരണോത്തരവ് നൽകി.</p> <p>പാർകിൻസ് എന്റർപ്രൈസസ് ന് 30.07.2022 ലെ ലറ്റർ ഓഫ് ഇൻഡന്റ് പ്രകാരം വിതരണം പൂർത്തിയാക്കാനായില്ല. 06.02.2023 ൽ 5,33,870 K.G ബ്ലീച്ചിങ് പൗഡറിനായി അവശ്യമനുസരിച്ച് വിഭാഗത്തിൽ നിന്നും കാരുണ്യ കമ്മ്യൂണിറ്റി</p>

		<p>വിഭാഗത്തിന് വീണ്ടും സപ്ലൈ ഓർഡർ നൽകി. 30.07.2022 ലെ വിതരണം പൂർത്തിയാക്കാത്തതുകൊണ്ട് 06.02.2023 ലെ അവശ്യമന്ദനം വിഭാഗം ആവശ്യപ്പെട്ട 5,33,870 KG BLEACHING POWDER ന്റെ LOI കാരുണ്യ കമ്മ്യൂണിറ്റി ഫർമസി വിഭാഗം ബാക്കെ ബിഹാറി എന്ന കമ്പനിക്കു നൽകുകയും 13.02.2023 ന് പ്രസ്തുത വിതരണക്കാരൻ അത് പൂർത്തിയാക്കുകയും ചെയ്തു.</p> <p>ഇതുമായി ബന്ധപ്പെട്ട കോർപറേഷൻ നടപടികൾ സംബന്ധിച്ച രേഖകളുടെ പകർപ്പുകൾ അനുബന്ധമായി ചേർക്കുന്നു.</p>
(ബി)	<p>2023-2024 സാമ്പത്തിക വർഷത്തിൽ കെ.എം.എസ്.സി.എൽ.-ൽ ബ്ലീച്ചിങ് പൗഡർ വാങ്ങിയത് ഏത് മാനദണ്ഡത്തിന്റെ അടിസ്ഥാനത്തിലാണെന്ന് വ്യക്തമാക്കാമോ; ടി ബ്ലീച്ചിങ് പൗഡർ വിതരണം ചെയ്യുന്നതുമായിട്ടുള്ള സപ്ലയേർസ് ആരൊക്കെയാണെന്നും അവരുടെ നിരക്ക് എത്രയാണെന്നും പ്രസ്തുത നിരക്ക് കെ.എം.എസ്.സി.എൽ.-ൽ ഏത് മാനദണ്ഡ പ്രകാരമാണ് അംഗീകരിച്ചതെന്നും നിരക്ക് നിശ്ചയിച്ചത് എത്ര അളവിനനുസരിച്ചാണെന്നും വ്യക്തമാക്കാമോ; രേഖകളുടെ പകർപ്പ് ലഭ്യമാക്കാമോ;</p>	<p>(ബി) 2023-24 സാമ്പത്തിക വർഷത്തിൽ പുതുക്കിയ സ്പെസിഫിക്കേഷനിലുള്ള Bleaching Powder Bleaching Powder (IS 1065), Minimum Strength of available Chlorine 32% എന്ന ഇനത്തിന് ഇ-ടെൻഡർ ക്ഷണിച്ചിരുന്നു എങ്കിലും യോഗ്യരായ വിതരണക്കാരെ ലഭിക്കാത്തതിനാൽ പ്രസ്തുത ഇനം കാരുണ്യ വിഭാഗം മുഖേന 19.06.2012 ലെ സ.ഉ. (കൈ) നം.186/2012/ആ.ക.വ. നം. സർക്കാർ ഉത്തരവ് പ്രകാരം സീൽഡ് ക്വട്ടേഷൻ ക്ഷണിച്ച് വിലപേശൽ പ്രക്രിയയിലൂടെ ലഭിച്ച 47.08 രൂപ നിരക്കിൽ 3,49,300 കിലോഗ്രാം ബ്ലീച്ചിംഗ് പൗഡർ പാർക്കിൻസ് എൻ്റെ പ്രൈസസിൽ നിന്നും സംഭരിച്ചു വിതരണം നടത്തുകയായിരുന്നു.</p> <p>ഇതുമായി ബന്ധപ്പെട്ട കോർപറേഷൻ നടപടികൾ സംബന്ധിച്ച രേഖകളുടെ പകർപ്പുകൾ അനുബന്ധമായി ചേർക്കുന്നു.</p>
(സി)	<p>2024-2025 സാമ്പത്തിക വർഷത്തിൽ കെ.എം.എസ്.സി.എൽ.-ൽ ബ്ലീച്ചിങ് പൗഡർ സംഭരിക്കാൻ എന്തുകൊണ്ട് ടെൻഡർ നടപടികൾ സ്വീകരിച്ചില്ല എന്ന് വ്യക്തമാക്കാമോ; പ്രസ്തുത നടപടി രേഖകളുടെ പകർപ്പ് ലഭ്യമാക്കാമോ?</p>	<p>(സി) 2023 -ൽ കൊല്ലം ഉളിയക്കോവിൽ, തിരുവനന്തപുരം കീൻഫ്ര, ആലപ്പുഴ എന്നീ ജില്ലാ മന്ദനം സംഭരണശാലകളിൽ ബ്ലീച്ചിങ് പൗഡർ സൂക്ഷിച്ച ഭാഗങ്ങളിൽ നിന്നാണ് തീപടർന്നതെന്ന റിപ്പോർട്ടിന്റെ അടിസ്ഥാനത്തിൽ ബ്ലീച്ചിങ് പൗഡറിന്റെ സംഭരണ വിതരണത്തിൽ അതീവ ശ്രദ്ധ ചെലുത്തേണ്ടതായി വന്നു. ആയതിനാൽ പ്രസ്തുത ഇനം മുൻ വർഷങ്ങളിലെപ്പോലെ മരണൊഴികെയുള്ള മറ്റു അനുബന്ധ സാമഗ്രികൾക്കായി ക്ഷണിക്കുന്ന വിഭാഗത്തിൽ ഉൾപ്പെടുത്തി ദർഘാസ് നടപടികളുമായി മുന്നോട്ടു പോകുവാൻ സാധിക്കുമായിരുന്നില്ല. മാത്രമല്ല, പ്രസ്തുത ഇനം സംഭരിക്കുന്നതിനായി ദർഘാസ് വ്യവസ്ഥകളും നിബന്ധനകളും പുതുക്കേണ്ടതായുണ്ട്. ദർഘാസ് വ്യവസ്ഥകളും നിബന്ധനകളും പുതുക്കുന്നത് വളരെ ഗൗരവമുള്ളതും ആയാസമേറിയതുമാണ്, ഇത് കുറ്റമറ്റ</p>

രീതിയിൽ ചെയ്യുന്നതിന് നിശ്ചിത സമയവും ആവശ്യവുമാണ്.

വലിയ അളവിൽ ബ്ലീച്ചിംഗ് പൗഡർ സൂക്ഷിക്കുന്നത് ഇത്തരം തീപിടുത്തങ്ങൾക്ക് ഇടയാകാം എന്ന കണ്ടെത്തലിനെ തുടർന്ന്, ജില്ലാ മരുന്ന സംഭരണകേന്ദ്രങ്ങളിലും സ്ഥാപനങ്ങളിലും ബ്ലീച്ചിംഗ് പൗഡർ മൊത്തമായി സൂക്ഷിക്കുന്നത് ഒഴിവാക്കുവാനും, ഇ-ടെൻഡർ ക്ഷണിച്ച് റണ്ണിംഗ് കോൺട്രാക്ട് ഫിക്സ് ചെയ്യുന്നതിനും കോർപ്പറേഷൻ തീരുമാനിച്ചു.

റണ്ണിംഗ് കോൺട്രാക്ടിനായുള്ള ദർഘാസ് ക്ഷണിക്കുന്നതിനായി വിതരണക്കാർക്കുള്ള പേയ്മെന്റ്സ്, സ്ഥാപനങ്ങളിൽ നിന്നുള്ള പർച്ചേസ് ഓർഡറുകൾ, സ്ഥാപനങ്ങളിലെ സപ്ലൈസ് സംബന്ധിച്ച വിതരണ വ്യവസ്ഥകൾ, ഡിഡിഎംഎസ് വഴി സ്ഥാപനങ്ങളിൽ നിന്നുള്ള പർച്ചേസ് ഓർഡറുകൾ തുടങ്ങിയവ സംബന്ധിച്ച ടെൻഡർ വ്യവസ്ഥകൾ തീരുമാനിക്കേണ്ടതായിട്ടുണ്ട്. ഇതിനായുള്ള ചർച്ചകൾ/ നടപടികൾ പുരോഗമിച്ചു വരുന്നു.

ബ്ലീച്ചിംഗ് പൗഡറിന്റെ ദർഘാസ് വ്യവസ്ഥകളും നിബന്ധനകളും പുതുക്കി ദർഘാസ് നടപടികൾ പൂർത്തീകരിക്കാൻ സമയമെടുക്കുമെന്നതിനാലും 2023-24 സാമ്പത്തിക വർഷം ബ്ലീച്ചിംഗ് പൗഡറിന് ദർഘാസ് ക്ഷണിച്ചെങ്കിലും യോഗ്യരായ വിതരണക്കാരെ ലഭിച്ചിരുന്നില്ല എന്ന അനുഭവത്തിന്റെ അടിസ്ഥാനത്തിലും നടപ്പു സാമ്പത്തികവർഷം ആദ്യപാദത്തിൽ മഴക്കാല ശുചീകരണ പ്രവർത്തനങ്ങൾക്ക് ഉപയോഗിക്കുന്നതിനായി, നടപ്പുസാമ്പത്തിക വർഷത്തെ (2024-25) ഇൻഡന്റിന്റെ 40% കാരുണ്യ കമ്മ്യൂണിറ്റി ഫാർമസി മുഖേന സംസ്ഥാന പൊതുമേഖല സ്ഥാപനമായ കെ.എസ്.ഡി.പി.എൽ-ൽ നിന്നും സംഭരിച്ച് വിതരണം ചെയ്തിട്ടുണ്ട്.

കോർപ്പറേഷന്റെ ആരംഭകാലം മുതൽ അവശ്യഘട്ടങ്ങളിൽ ദർഘാസ് നടപടികൾ കൂടാതെ കെ.എസ്.ഡി.പി. എൽ-ൽ നിന്നും നേരിട്ട് മരുന്നുകൾ വാങ്ങിവരുന്നുണ്ട്.

ഇതുമായി ബന്ധപ്പെട്ട കോർപ്പറേഷൻ നടപടികൾ സംബന്ധിച്ച രേഖകളുടെ പകർപ്പുകൾ അനുബന്ധമായി ചേർക്കുന്നു.



Extract of the Minutes of the Meeting of 37<sup>th</sup> Board of Directors of  
KMSCL held on 20<sup>th</sup> November, 2014

Karunya Community Pharmacy (Procurement) DIVISION

Agenda Item No : 37.03

Constitution of Committee for – Revision of purchase rate /  
Introducing New Products of Existing Company / New Company :

Managing Director informed the Board that 24 Numbers of Karunya Community Pharmacy outlets are established in various districts of which 22 numbers are functioning regularly and 2 numbers at Pampa & Sannidhanam during Mandala - Makaravilaku Season. The Construction of another 12 numbers are nearing completion. It was further informed that the rate for many of the items were fixed during the year 2012-13 .The companies have submitted their revised rate for the year 2014-15 and moreover many companies have expressed their unwillingness to bill with the existing old rates fixed during previous years. It was further informed that as per G.O. (MS) No.186/2012/H&FWD dated : 19-06-2012 the Managing Director, Kerala Medical Services Corporation Limited is authorized to procure branded drugs without tender but through price negotiation as is being done by Supplyco and to sell them at a margin in conformance with the objective of the Government.

*Resolution No.37.03*

*The Board discussed the matter and decided to constitute a separate committee called price approval committee which will approve the rates fixed by the negotiation committee and it was resolved to form a Price approval Committee consisting of following members.*

Members of Committee:

1. Managing Director, KMSCL.
2. Finance Member of Board, KMSCL.
3. Drugs Controller of the State.
4. Professor and Head,  
College of Pharmaceutical Sciences,  
Medical College, Thiruvananthapuram.

Board further Resolved that price approved by the approval committee will be for at least one year time. However if there is reduction of price of the drug in the market revision of the price shall be effected accordingly.

Board further noted that there is no mechanism to check the actual need or quantity of drugs to be purchased or to approve list of drugs / new drugs to be purchased. After further discussions.

*Resolution 37.03(a)*

*Managing Director*  
Managing Director

*Chairman*  
Chairman

*It was resolved to constitute a drug inclusion Purchase committee consisting of Managing Director, Director of Health Services and Director of Medical Education who will also periodically look after the necessity of medicines.*

---

Agenda Item No : 37.04

Re constitution of price negotiation committee :

---

Managing Director informed that twenty two Karunya Community Pharmacy outlets are functioning regularly, including five in Govt. Medical Colleges. Now KMSCL has planned to start ten more outlets. The companies have submitted their revised rate for the year 2014-15. New companies have given their quotations and existing companies want to introduce their new products. Existing rates was fixed during the year 2012-13. The companies started billing with the new rate. Presently the hikes in rates are not accepted and the increased rates are deducted from the bills/invoices. Many companies have expressed their unwillingness to bill with the existing old rates fixed during previous years. Bulk procurement of medicines/surgicals are in need as the sales and numbers of outlets are increasing. With bulk procurement price advantage of special rate can be obtained for Karunya Community Pharmacy. The Managing Director have reconstituted the existing price negotiation committee vide order No.KMSCL/ CPS/133-PNC/2012 dtd : 27-10-2014 with the following members.

Members of Committee :

- |  |                 |
|--|-----------------|
| 1. Smt. Asitha Bai S., General Manager                     | - Chair person  |
| 2. Shri. K.J. Dileep, Purchase Manager (Drug & Equipments) | - Vice Chairman |
| 3. Shri. V Mohankumar, Finance Manager, KMSCL              | - Member        |
| 4. Shri. Sajit.U, Deputy Manager (CPS-Procurement)         | - Convener      |
| 5. Shri. Salji S., Deputy Manager (i/c) (CPS-Sales)        | - Member        |

Resolution No.37.04

*The Board ratified the action of Managing Director in forming the price negotiation committee consisting of Shri. K.J. Dileep, Purchase Manager, Shri. V. Mohan Kumar, Finance Manager, Shri. Sajit. U, Deputy Manager (CPS - Procurement) and Shri. Salji. S. Deputy Manager (i/c) (CPS- Sales) and decided to exclude Smt. Asitha Bai. S., General Manger since she is absenting from her duties after offer of resignation recently and decided to include in the committee the next person who takes charge of General Manager, KMSCL.*

*Hanya*  
Managing Director

*[Signature]*  
Chairman

Minutes of the Meeting held on 16.05.2024 at the Chamber of Managing Director, KMSCL with KSDPL regarding the review of the supplies for the year 2023-24, procurement for the year 2024-25 and the supply of Bleaching Powder for the year 2024-25.

The Managing Director KMSCL, Sri. Jeevan Babu K IAS chaired the meeting. The following officers attended the meeting;

Sl. No.	Name	Designation
1.	Sri. E. A Subramanian	Managing Director, KSDPL
2.	Dr. Shibulal.A.	General Manager, KMSCL
3.	Smt. Arifa Beegum S. R.	Deputy Manager - KCP Purchase
4.	Smt. Kavitha V. T.	Assistant Manager - Essential drug Division
5.	Sri. Ratheesh M.	Assistant Manager - Supply Chain management

The Managing Director, KMSCL briefed the purpose of the meeting. The review of the supplies for the year 2023-24, procurement for the year 2024-25 and the supply of bleaching powder for the year 2024-25 were the Agendas of the meeting.

The discussions were as follows;

I. Default Supplies from KSDPL for the year 2023-24

The current status of procurement of drugs from KSDPL for the year 2023-24 was discussed in detail. For the year 2023-2024, KMSCL placed orders with KSDPL for their eligible quantity for 93 items, M/s KSDPL has not completed the supply of 100% even after 122-354 days from the date of purchase orders. It conveyed that the default in supplies from KSDPL cannot be accepted further

KSDPL ensured that all the supplies would be completed by May 2024. MD, KSDPL explained that only one product line of their manufacturing unit is functioning properly and they are trying to cater the items on time.

II. Procurement of drugs from KSDPL for the year 2024-25



MD, KSDPL claimed that for the year 2024-25 M/s. Kerala State Drugs and Pharmaceutical Ltd offered 83 items in Category I & II (Drugs) and 5 items in Category III-VIII (Drugs/Supplies).

MD, KSMCL explained that, from the 83 items offered by KSDPL, 4 items were rejected by the BoD for non-submission of product approval, 1 item was rejected due to rate hike when compared to the open market, 14 items for which the rate quoted by KSDPL is the lowest/within the price band of L1+15, the BoD accepted the rates and accordingly LOI and purchase orders were placed with KSDPL. For the remaining 64 items the rate offered by KSDPL is more than L1 + 15% and KSDPL was directed to match their price with L1 as per the tender conditions and G.O (Rt) No. G.O.(Rt.) No. 5382/2020/Fin dated 18.09.2020.

MD, KSDPL requested that they are ready to supply 59 products out of 64 at the price preference of L1+15% and to accept the offer of 59 items with L1+15% rate as done in previous years.

MD, KMSCL directed that a Government order is needed to clarify this issue.

### III. Procurement of Bleaching Powder for the year 2024-25

Due to the fire Accidents occurred at three drug warehouses in Kollam Uliyakovil (17.05.2023), Thiruvananthapuram KINFRA (22.05.2023), and Alappuzha (27.05.2023). It was decided, not to store Bleaching Powder in Bulk quantity at the warehouses of the corporation. It was decided to invite separate tenders for the procurement of the same and to supply the item directly to the institutions in the 75<sup>th</sup> BoD held on 16.02.2024. In this regard, the tender conditions on the supply, delivery conditions, quantity to be purchased, placing of purchase orders, payment to the suppliers, etc yet to be decided. Hence to meet the anticipated emergency requirement during the monsoon season, it is decided to procure up to 40% of the tendered quantity at the earliest.

The MD. KMSCL briefed that, during the online meeting held on 30.04.2024 on Monsoon Diseases and its prevention and control, Hon. Health

Minister directed KMSCL to ensure the availability of all the drugs/supplies required for Monsoon season including Bleaching Powder.

MD, KMSCL evaluated the status of e-tender for the year 2024-25 on 14.05.2024 with KSMCL officials, had directed to make immediate arrangements to procure Bleaching Powder which is critically required for Monsoon season. After detailed discussions, it was decided to seek feasibility from KSDPL for the supply of Bleaching Powder.

In this regard, General manager KMSCL discussed the feasibility of supply of bleaching powder through KSDPL with Managing Director KSDPL. The outcome of the discussion was that KSDPL has expressed their willingness to supply the bleaching powder to KMSCL. Further General Manager, KMSCL had directed KCP to forward a mail requesting to provide the rate of Bleaching Powder.

MD, KSDPL intimated their willingness to supply the same. Also intimated that they may be able to supply Bleaching Powder in 25 Kg. packets. It is also requested to provide 15% hike from last year KCP rate.

Existing KCP rate	KSDPL offered rate
47.082	54.14

#### Decisions of the meeting.

1. All the supplies against purchase orders issued for the year 2023-24 to KSDPL shall be completed by May 2024.
2. Regarding the KSDPL offered items for which purchase orders were not issued for the year 2024-25 due to rate hike (rate more than L1 + 15%), it was decided that a Government order has to be obtained for clarifying the issue.
3. To meet the criticality, up to 40% requirement of Bleaching Powder for the year 2024-25 shall be procured from KSDPL through KCP. KSDPL

shall ensure the supply of Bleaching Powder within 20 days from the date of purchase order. The supplies shall be made by KSDPL at the District Drug Warehouses of the Corporation accordingly as per the delivery schedule provided by KMSCL.

4. It was decided to have further negotiation and KCP was directed to negotiate with KSDPL to arrive rock bottom price for Bleaching Powder before issuing purchase order.



Managing Director  
Kerala Medical Services Corporation Ltd



**Extract of the minutes of the meeting of  
68<sup>th</sup> BoD of KMSCL held on 10.05.2022**

**ESSENTIAL DRUGS DIVISION**

Item No : 68.01

**Confirmation of the Previous Minutes**

The minutes of the previous meeting was discussed & confirmed as there were no comments or suggestions.

Agenda Item No : 68.02

**Action Taken Report on the resolutions of 67<sup>th</sup> meeting of the board of directors held on 5<sup>th</sup> November 2021**

The Board noted Action Taken Report presented by the Managing Director.


Agenda Item No : 68.03

**E-tender for the Procurement of Drugs (CAT I & II) and Specialty Drugs for the year 2022-23 :**

1. The 67<sup>th</sup> meeting of Board of Directors held on 05.11.2021 vide Resolution no. 67.03 has authorized the Managing Director to invite e-tenders for the procurement of drugs/supplies in the Essential Drug List and Specialty Drug List for the consolidated annual indent quantities submitted by DHS, DME, NHM, KSACS & Prisons for the year 2022-23 with revised tender conditions and final revised drug list.
2. E-tenders were invited for the Procurement of Drugs/supplies for the year 2022-23 for 741 items (except Anti Cancer Drugs) for the quantities approved by the 67<sup>th</sup> meeting under the following categories.

Sl. No.	Category	Tender no. & date	No. of items
1	Drugs (Cat I & II)	KMSCL/ED/I&II/RC/2021/014 Dated 04.12.2021	402
2	Drugs/Supplies (Cat III - VIII)	KMSCL/ED/III-VIII/RC/2021/015 Dated 04.12.2021	155
3	Specialty Drugs(SDL)	KMSCL/ED/SPL/RC/2021/016 Dated 04.12.2021	184
Total			741


  
Dr. SRIRAM VENKITARAMANIAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

3. The Technical Bids against the e-tenders were opened on 31.12.2021. The technical evaluation of the bids submitted was conducted by officers from the Directorates of Health Services, Medical Education and Drugs Control Department at the Head office of the Corporation.
4. Notices on the observations of the technical bid evaluation against e tenders for Drugs (Cat I & II) and Specialty Drugs were published on 22.02.2022 inviting complaints/suggestions, if any.
5. A meeting of sub-committee of Board of Directors comprising of ~~Drugs Controller and Professor, College of Pharmaceutical Sciences, T.D Medical College, Alappuzha~~ (on behalf of Professor & Head, College of Pharmaceutical Sciences, Thiruvananthapuram) for scrutinizing the complaints/ suggestions received in response to the notices published on status of technical bid evaluation was convened on 16.03.2022 to 19.03.2022 at the head office of the Corporation. The sub-committee evaluated the complaints/ representations and also the additional documents received and the decisions were taken based on the merits.
6. As part of technical evaluation, Factory inspection was to be conducted for those firms which were not inspected during the past three years and the manufacturing premises of the new bidders/Loan Licensees participated. But due to the prevailing situation of COVID-19 / Omicron, factory inspection could not be conducted this year and Government of Kerala vide G.O. (Rt) No.188/2022/ H&FWD dated 22.01.2022 has accorded permissive sanction for deferring the factory inspection against the tenders mentioned above.
7. The notices on the status of selected/rejected bidders/products and decision taken by the sub-committee on the complaints/ representations on technical bid evaluation of Drugs (cat I & II) and Specialty Drugs were published on 23.03.2022.
8. Enoxaparin Injection offered by M/s. Bharath Serums & Vaccines Ltd. - Debarment of the item by Madhya Pradesh Public Health Services Corporation - reg.

Madhya Pradesh Public Health Services Corporation Ltd vide Order no. 9178/F/267/MPPHSCL/Technical/2021 dated 21.09.2021 had debarred the item Enoxaparin Injection for 2 years. The firm vide WP. 28382 of 2021 had filed Writ Petition in the Hon' High Court of Madhya Pradesh to Quash the Order dated 21.09.2021. The Hon' High Court vide Order dated 21.12.2021 had made clear that the Order dated 21.09.2021 will apply only in the State of MP till next date of hearing. As per the latest hearing dated 09.03.2022

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

Interim Order shall continue till next hearing after 2 weeks. The Subcommittee of the BoD had examined the case and opined that Offer of the firm for Enoxaparin Injection deferred till final verdict from Honorable Court. Hence the qualification of the item Enoxaparin Injection for award of contract to the firm will be subject to the final verdict of the Hon' High Court.


9. Blacklisting of M/s. Health Biotech Limited by M/s Karnataka State Medical Supplies Corporation Limited (KSMSCL)

The firm is blacklisted by M/s Karnataka State Medical Supplies Corporation Limited (KSMSCL) for 5 years from 25.10.2021 to 24.10.2026 vide order KSMSCL/NSQ/01/BLACKLIST(B)/2021-22 dated 25.10.2021 for Quality failure. Honourable High Court of Karnataka vide Interim Order dated 03.12.2021 had stayed the Blacklisting order of 'KSMSCL'. The Subcommittee of the BoD had examined the case and opined that qualification is respect to the final verdict from the Honorable Court. Hence the qualification of the firm M/s. Health Biotech Limited for award of contract to the firm will be subject to the final verdict of the Hon' High Court.

10. The price bids of the eligible bidders were opened online on 24.03.2022 and evaluated.
11. Notice on Supplier wise rate quoted and drug wise bid status was published on 30.03.2022.
12. Representation was received from a bidder stating that even though they have quoted the same basic price of the L1 bidder, they were awarded as L2 bidder due to difference in rounding off the GST value portion and requested to correct it, and award them as Joint L1 bidder for the item.
13. As per clause 6.10.8 "The total of rates quoted in column No. 12 of BOQ (Landed price) will be considered for bid ranking." Hence further correction in the bid ranking status was not permitted.
14. On receipt of this representation, the GST values submitted by all the bidders were further scrutinized and various errors were noted. Hence it was decided to publish revised notice on supplier wise rate quoted with revised GST value.
15. Basic Price and GST value has been revised accordingly to four decimal places (with the actual GST % in the price breakup) without any change in the Final price and Bid ranking Status.
16. The drug wise bid status and revised supplier wise rate quoted were published on 22.04.2022 requesting the bidders to verify their prices and no further queries regarding the revised supplier wise rate were received from any of the bidders.



Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.




Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

17. Rejection of M/s Bharat Parentrals Ltd in Technical Evaluation

- a. M/s Bharat Parentrals Ltd, Vadodara had participated in the tender KMSCL/ED/I&II/RC/2021/014 Dated 04.12.2021 and quoted for 56 items, out of which 12 items were technically rejected during document evaluation.
- b. The offer of the firm was rejected by the Corporation for the reason that firm is debarred/deregistered by Medical Store Organization (GMSD) New Delhi for the supply of all drugs for a period of 5 years from ~~05-04-2021 to 04-04-2026 due to repeated quality failure.~~
- c. M/s Bharat Parentrals Ltd, Vadodara had challenged their rejection against the tender KMSCL/ED/I&II/RC/2021/014 Dated 04.12.2021 in the Honorable High Court of Kerala vide WP(C)No.12559 of 2022 (T) dated 06.04.2022. The Honorable High Court of Kerala had admitted their petition and next posted on 20.05.2022, and directed to complete the pleading by then and ordered that the rejection of any tender quoted by the petitioner will be subject to the outcome of the writ petition.
- d. Hence legal opinion was sought in this regard and Standing Counsel opined that there is nothing in the order of the Hon. High Court stopping or pausing the tender finalization process. However, in light of the interim order the LoIs and any other communications accepting the tenders of any other supplier after rejecting the better offers of the petitioner can include the following words "The award of the contract under the tender to you will be subject to the result of WP[C] 12559/22 filed by M/s Bharat Parenterals Ltd., in the Hon. High Court of Kerala". Subject to the aforesaid, there is no bar in the KMSCL going ahead and completing the tender process by excluding the petitioner and awarding the tenders to any other supplier.

18. The provisional bid ranking status were published on 26.04.2022, also the L1 bidders were requested to furnish their rock bottom price by e-mail on or before 05.00 PM on 27.04.2022.
19. During the online negotiation conducted with the L1 bidders, 8 bidders have responded and 4 bidders have reduced their rate for 35 items.
20. It was noted that the rate quoted for the following items is higher than the ceiling price fixed by NPPA.

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department



Drug Code	Drug Name	L1 bidder 2022-23	Quoted rate 2022-23 (Rs.)	Ceiling Price fixed by NPPA (Rs.)	NPPA rate (inclusive of GST) (Rs.)
D05019	CHLORPHENIRAMINE MALEATE TAB IP, 4mg 1 No	Agog Pharma Ltd	0.1456	0.10	0.112
D17002	CHLORPROMAZINE TAB IP, 50mg 1 No	Geniurion Remedies pvt Ltd	1.1088	0.42	0.4704
D02006	CLOXACILLIN CAP IP, 250 mg, 1 No	Nestor Pharmaceu ticals Ltd	1.4840	1.26	1.4112

The rate of CHLORPROMAZINE TAB IP and CLOXACILLIN CAP IP, 250 mg, were reduced to ceiling price fixed by NPPA by the bidder

The rate of the CHLORPHENIRAMINE MALEATE TAB IP, 4mg was not reduced by the bidder to the ceiling price fixed by NPPA or lesser hence the rate of these item has been reduced to the ceiling price fixed by NPPA as per Clause 6.8.7.

Drug Code	Drug Name	L1 bidder 2022-23	Quoted rate 2022-23 (Rs.)	Ceiling Price fixed by NPPA (Rs.)	NPPA rate (inclusive of GST) (Rs.)
D05019	CHLORPHENIRAMINE MALEATE TAB IP, 4mg 1 No	Agog Pharma Ltd	0.1456	0.10	0.112

21. **Blacklisting of M/s-Unicure (India) Ltd. by Chattisgarh Medical Services Corporation Ltd (CGMSC)**

- a. M/s Unicure (India) Ltd., C-22 and 23, Sector-3, Gautam Budh Nagar, Noida (UP) has become L1 bidder for 78 items in the following e-tenders invited by KMSCL for the year 2022-23.

Sl. No.	Tender no.	No. of items for which M/s Unicure India Ltd is the L1
1.	KMSCL/ED/I&II/RC/2021/014 Dated 04.12.2021	72
2.	KMSCL/ED/SPL/RC/2021/016 Dated 04.12.2021	5
Total		77

Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.


Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

- b. It was noticed that Chattisgarh Medical Services Corporation Ltd (CGMSC) had blacklisted M/s Unicare India Ltd from 12.04.2022 to 12.04.2024 for the reason that they does not fulfil tender terms and conditions (failed to intimate the information regarding product blacklisted by KMSCL).
- c. KMSCL had blacklisted the product Vitamin APaediatric oral solution IP 100000 IU/ml, 100ml bottle supplied by M/s Unicare India Ltd due to declaration of Not of Standard Quality vide order N0.62/2021 dated 07.05.2021 upto 06.05.2024.
- d. M/s Unicare India Ltd. was the L1 supplier for the product Vitamin APaediatric 100000 IU/ml, Oral solution IP in the tender dated 23.08.2019 invited by CGMSC for the year 2019-20. Accordingly they entered into Contract agreement on 21.10.2019 for one year upto 21.10.2020. Further extended the contract for 6 months upto 21.04.2021.
- e. Since KMSCL had blacklisted Vitamin A paediatric oral solution IP 100000 IU/ml, 100ml bottle after the contract period is over (ie., 07.05.2021), M/s Unicare India Ltd. challenged the matter in WPC No. 1961/2022 before the High Court of Chhattisgarh, Bilaspur. Considering the fact the Hon<sup>ble</sup> court vide interim order dated 25.04.2022 granted interim stay till the next date of hearing and directed to list the case after two weeks.
- f. Since KMSCL is in the process of finalising the e-tenders invited for the year 2022-23, legal opinion from the Standing counsel was sought in this regard.

22. The status after negotiation is shown below;

Sl. No.	Tender no.	No. of items tendered	Bidders Participated	Bidders rejected in TE evaluation	Bidders qualified for PB evaluation	No. of items for which rates are received	No bidder items
1.	KMSCL/ED/II/RC/2 021/014 Dated 04.12.2021	402	79	5	74	349	53
2.	KMSCL/EU/SPL/RC/2 021/016 Dated 04.12.2021	184	43	7	39	82	102
Total		586	122	12	110	431	155

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.


  
Dr. RAJAN N. KHOBRADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

23. The comparison of rates received after negotiation with that of previous year tender (2021-22), ceiling price fixed by NPPA and Karunya Community Pharmacy Services is as follows;

Sl. No.	Particulars	I & II	SPL	Total	Remarks
I	No. of items tendered	402	184	586	
II	No bidder items (Annexure I)	53	102	155	
III	No. of items for which rates received	349	82	431	
IV	No. of items having single bidders	73	45	118	
V	No. of items for which rates can be compared with previous year rates	327	70	397	
1.	Items where rates are lesser than/equal to 20% rate hike of 2021-22 rates	283	57	340	
	a. Less than 2021-22 rate (Annexure II)	184	39	223	KCP rates for 11 items is lesser than tender rates
	b. Equal to 2021-22 rate(Annexure III)	7	4	11	
	c. Greater than 2021-22 rate up to 20% (Annexure IV)	92	14	106	KCP rates for 6 items is lesser than tender rates
2.	Items where rates are between 20-50% rate hike of 2021-22 rates	31	5	36	
	a. Items having rates lesser than KCP rates (Annexure V)	17	5	22	
	b. Items having rates higher than KCP rates (Annexure VI)	3	-	3	
	c. Items having no rates in KCP (Annexure VII)	11	-	11	
3.	Items where rates are between 50-100% rate hike of 2021-22 rates	8	6	14	
	a. Items having rates lesser than KCP rates (Annexure VIII)	6	5	11	
	b. Items having rates higher than KCP rates	-	-	-	
	c. Items having no rates in KCP (Annexure IX)	2	1	3	

Draft #3 of File KMSCL/ADMIN/11437/2024 Approved by General Manager on 29-Jun-2024 02:26 PM - Page 25

  
 Dr. SRIRAM VENKITARAMAN IAS  
 Managing Director,  
 Kerala Medical Services Corporation Ltd.

  
 Dr. RAVAN N. KHOBRAGADE IAS  
 Chairman, KMSCL &  
 Principal Secretary to Government,  
 Health & Family Welfare Department.


4.	Items where rates are above 100% rate hike of 2021-22 rates	5	2	7	
a.	Items having rates lesser than KCP rates (Annexure X)	4	2	6	
b.	Items having rates higher than KCP rates	-	-	-	
c.	Items having no rates in KCP (Annexure XI)	1	0	1	
5.	Items having no rates in 2021-22 tender	22	12	34	
a.	Items having rates lesser than KCP rates (Annexure XII)	8	7	15	
b.	Items having rates higher than KCP rates (Annexure XIII)	6	2	8	
c.	Items having no rates in KCP (Annexure XIV)	8	3	11	

Sl. No.	Department	No. of items in the list	No. of items Indented	No. of items for which rates received for 2022-23	Indent Value with L1 rate 2022-23 (Rs.)
<b>ESSENTIAL DRUGS</b>					
1.	DHS - General	603	602	380	3,059,944,029.54
2.	DHS - MHP	45	45	41	83,996,410.23
3.	DME - General	603	561	354	856,122,280.64
4.	KSACS(GST) DHS	75	74	51	590,130.11
	KSACS(GST) DME			43	762,628.44
5.	NHM - UPHC	282	278	208	86,670,815.16
6.	Prisons	282	247	195	2,858,834.08
<b>Total Value EDL</b>					<b>4,090,945,128.20</b>
<b>SPECIALTY DRUGS</b>					
7.	DME	184	184	82	331,948,057.34
8.	DHS	184	0	0	-
9.	DHS - MHP	45	45	41	83,996,410.23
<b>Total Value SDL</b>					<b>415,944,467.57</b>
<b>Grand Total Value (Rs.)</b>					<b>4,506,889,595.77</b>

**Resolution No.68.03**


1. After detailed discussion and deliberation the Board resolved to decide that the base price quoted by the bidder has to be kept constant and calculation of GST has to be done accordingly to derive the landing price. The base price should not be changed or revised and all companies are duty bound to pay appropriate GST. The calculation of GST should be done based on the rates laid down in Government notifications. The Board also directed the MD to seek legal opinion in this regard.

  
**Dr. SRIRAM VENKATARAMAN IAS**  
 Managing Director,  
 Kerala Medical Services Corporation Ltd.

  
**Dr. RAJAN N. KHOBRADE IAS**  
 Chairman, KMSCL &  
 Principal Secretary to Government,  
 Health & Family Welfare Department.

2. *The Board authorized the MD to proceed with finalizing the tenders based on this re-calculation principle, to seek legal opinion,, and to follow further due process and to place orders with the successful L1 bidder once the re-calculation is finalized.*
3. *Further the Board discussed about the comparison of rates received after negotiation with that of previous year's tender (2021-22) and available KCP rates.*
  - a. ~~*For items where the rates received in the tender were lower than available KCP rates, these rates were approved.*~~
  - b. *In cases where existing KCP rates were lower than rates received in the tender, the items may be procured through KCP based on these available KCP rates.*
  - c. *The board directed the MD to calculate Quarter-wise projections for quantities of each item that would be required in this year (2022-23) based on the consumption pattern in the same quarters over the previous five years.*
  - d. *For orders placed through KCP, the quantity of order may be limited to the quantity projected for Quarter 1. Orders for quantities projected for Quarter 2 may be placed after two months.*
4. *The Board also directed the MD to completely revamp the KCP process and to put up a proposal within two weeks.*
5. *The Board also directed the MD to explore the possibility of procuring through the GeM portal of the Government of India so as to discover better rates by ensuring wider competition at the national level.*
6. *While discussing the various cases where litigations were pending in various Courts, the Board directed the MD to place orders with L2 bidders for the quantities projected for Quarter 1. It further instructed the MD to ensure that in all Purchase Orders that were being placed with L2 bidders in such circumstances, a clear clause stating that the Purchase Order is subject to the final outcome of the particular case (details to be included).*
7. *The Board directed the MD to inform the concerned Court of this strategy that the Corporation was following, and to request the Court to ensure timely disposal of the case to ensure timely procurement and prevention of supply chain disruptions.*

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

8. In all such cases where orders were to be placed with L2 bidders, the Board instructed the MD to negotiate with the L2 bidder and explore the possibility of matching L1 rates.


Agenda Item No : 68.04

**Procurement of drugs from M/s Kerala State Drugs and Pharmaceuticals Limited for the year 2022-23 :**

1. E-tender for the procurement of drugs for the year 2022-23 was invited vide e-tender No.KMSCL/ED/I&II/RC/2021/014 Dated. 04.12.2021 and the Technical Bids were opened and scrutinized.
2. M/s. Kerala State Drugs and Pharmaceutical Ltd (KSDPL), a State Public Sector Undertaking had participated in the e-Tender and offered 57 items. The documents submitted by the firm were evaluated and the discrepancies noted were intimated to them vide letter dated 18.02.2022.
3. The reply received from the firm vide their letter dated 25.02.2022 was scrutinized and following observations were made

TABLE-1	
Description	No. of items
Total No. of items offered by M/s.KSDPL for the year 2022-23	57
Items supplied by M/s. KSDPL during the Fin. year 2020-21 were declared as Not of Standard Quality a. Amoxicillin Oral Suspension IP 250 mg/5 ml, 60 ml Bottle (13 batches) b. Acetylsalicylic Acid Tab IP(Gastro-Resistant) 75 mg (10 batches)	2
Items for which product permit was issued on 05.12.2021 and not having Market Standing for 3 years (Metformin HCL Sustained Release Tab IP 500 mg)	1

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.


  
Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

<p>No of items Manufactured under the License no. 9/25/74 and 10/28/7. for which GMP Certificate not submitted</p> <p>The firm represented that GMP certificates of these licence nos. are under process and in the previous years the Corporation had accepted the offer of the items Manufactured under the License no. 9/25/74 and 10/28/7 without GMP .</p> <p>The Government vide Order No. G.O.(Ms) No. 154/2008 - 09/H&amp;FWD dated 15.05.2008 has directed the Corporation to purchase items from KSDPL without resorting to tender formalities and without insisting GMP certificate conditions, in relaxation to Store Purchase rule subject to actual requirement of KMSCL.</p>	38
---	----

4. A meeting of sub-committee of Board of Directors comprising of Drugs Controller and Professor, College of Pharmaceutical Sciences, T.D Medical College, Alapuzha (on behalf of Professor & Head, College of Pharmaceutical Sciences, Thiruvananthapuram) for scrutinizing the complaints/suggestions received in response to the notices published on status of technical bid evaluation was convened on 16.03.2022 to 19.03.2022 at the head office of the Corporation. The Committee had scrutinized the documents from the firm and the following decisions were made.

Sl. No.	Name of the item	Observation	Decision of Sub Committee
1.	D02033- Amoxicillin Oral Suspension IP 250 mg/5 ml, 60 ml Bottle (13 batches)	Items supplied by M/s. KSDPL during the Fin. year 2020-21 were declared as Not of Standard Quality by KMSCL.	Rejected the offer of these items
2.	D13024- Acetylsalicylic Acid Tab IP(Gastro-Resistant) 75 mg (10 batches)		
3.	D21076- Metformin HCL Sustained Release Tab IP 500 mg.	<ol style="list-style-type: none"> <li>1. Details of 3 batches not mentioned in the Performance Statement (Anx IV) Submitted.</li> <li>2. The firm represented that they have received Product Permit for Metformin HCL Sustained Release Tab IP 500 mg with effect from 05.12.2021 only.</li> <li>3. Firm had offered item from License no. 9/25/74 and 10/28/7 which do not have WHO -GMP Certificate.</li> </ol>	Decision regarding the acceptance/Rejection of the offer for the item may be decided by BoD.

  
 Dr. SRIRAM VENKITARAMAN IAS  
 Managing Director,  
 Kerala Medical Services Corporation Ltd.

  
 Dr. RAJAN N. KHOBRADE IAS  
 Chairman, KMSCL &  
 Principal Secretary to Government,  
 Health & Family Welfare Department.


4.	38 items	<p>The firm had offered 38 items from Licence no. 9/25/74 and 10/28/7 but no GMP certificate submitted.</p> <p>The Government vide Order No. G.O.(Ms) No. 154/2008 - 09/H&amp;FWD dated 15.05.2008 had directed the Corporation to purchase items from KSDPL without resorting to tender formalities and without insisting GMP certificate conditions, in relaxation to Store Purchase rule subject to actual requirement of KMSCL.</p> <p>The firm had represented vide letter dated 25.02.2022 that GMP certificates for these licence nos. are under process and in the previous years the Corporation had accepted the offer of the items Manufactured under the License no. 9/25/74 and 10/28/7 without GMP certificate.</p>	<p>Decision regarding the acceptance/Rejection of the offer for these items may be decided by BoD.</p>
----	----------	---	--

5. M/s.KSDPL possess manufacturing licence and product permit to manufacture and supply 57 products.
6. The price bid of M/s. KSDPL and the other bidders qualified in the tender were opened on 24.03.2022.
7. Rate offered by KSDPL for 54 items are higher than L1 rate.
8. M/s KSDPL had offered to supply following items which have no eligible bidder in the tender and also no comparable rate in KCP.

Item Code	Drug Name	Tender Qty	Rate 2021-22 (Rs.)	Rate 2022-23 (Rs.)	% Hike
D02101	Cephalexin Cap IP 500 mg 1 No	34,690	3.6547	12.32	237%
D02002	Co-Trimoxazole Oral Suspension IP 40mg+200mg 50 ml Bottle	14,572	13.5951	20.16	48%
D02094	Cefazolin Sodium Injection IP 1gm Vial	24,265	27.4176	27.5632	0.53 %

9. Based on the Govt. order G.O.(Rt.) No. 5382/2020/Fin dated 18.09.2020, the strategy adopted for the procurement of drugs offered by M/s. KSDPL for the year 2021-22 was as follows;

  
**Dr. SRIRAM VENKITARAMAN IAS**  
 Managing Director,  
 Kerala Medical Services Corporation Ltd.

  
**Dr. RAJAN N. KHOBRAGADE IAS**  
 Chairman, KMSCL &  
 Principal Secretary to Government,  
 Health & Family Welfare Department.



a. Purchase preference :

- i. The LOI and Purchase Orders for 100% of the tender volume were placed to M/s. KSDPL for those items for which no other offer were received against the tender.
- ii. LOI for 50% of tender Volume were placed with M/s KSDPL for those products where there was no SSI competition with a price preference of L1+ 15 % were available against the tender.
- iii. LOI for 35% of tender Volume were placed with M/s KSDPL for those products for which there was SSI competition with a price preference of L1+ 15 % were available against the tender.

b. Price preference: Price preference of L1+15% of 2021-22 tender approved rates or the rates offered by M/s. KSDPL whichever is less.

10. Division of tender quantities to KSDPL for the year 2022-23


Based on the last year's division of tender quantities, the division of tender quantities for the year 2022-23 may be adopted as per the table listed below:

TABLE-2	
Purchase preference	Reasons
100% of tender volume	Those product in which KSDPL is L1 (KSDPL is single bidder)
50% of tender Volume	For those products there was no SSI competition with a price preference of L1+ 15 %.
35% of tender Volume	For those products there was SSI competition with a price preference of L1+ 15 %.

**Resolution No.68.04**

1. *The Board permitted the MD to reject the offers of items supplied by KSDPL which were declared as Not of Standard Quality by KMSCL during the financial year 2020-21.*
2. *The Board permitted the MD to accept the offer of 38 items that lacked GMP certificate*
3. *The Board permitted the MD to accept the offer of KSDPL regarding the product D21076- Metformin HCL Sustained Release Tab IP 500 mg since it had already received the Product Permit at a later date, and directed the MD to ensure that the permit was valid and in place before placing orders.*

  
Dr. SRIRAM VENKITARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

4. The Board permitted the MD to accept the offer of the remaining items with price preference of L1 + 15%.
5. The Board directed the MD to place orders with KSDPL based on the suggestion made in the agenda.
6. In cases where KSDPL was the sole bidder, orders may be placed with Price preference of L1+15% of 2021-22 tender approved rates or the rates offered by M/s. KSDPL whichever is less.


Agenda Item No : 68:05

**Procurement of Equine Anti Rabies Immunoglobulin Inj, 300 IU/ml (ERIG) from M/s. VinsBioproducts Ltd. :**

1. M/s VinsBioproducts Ltd was the L1 bidder for Equine Anti Rabies Immunoglobulin Inj, 300 IU/ml for the year 2021-22 @ Rs.154.35/-, accordingly Letter of intent for 1,26,850 nos and 1<sup>st</sup> Purchase order for 50,740nos. were placed with L1 bidder on 17/04/2021 & 21/04/2021 respectively. The supply was started as per the schedule stipulated in the tender document.
2. Adverse drug reactions were reported from various Hospitals against the batches of Equine Anti Rabies Immunoglobulin Inj 300 IU/ml supplied by M/s VinsBioproducts Ltd. Hence the item supplied by M/s. Vins Bioproducts Ltd was freezed by the Corporation and the details are shown below.

Sl. No.	Batch No	Nature Of Complaints	Institution	Complaint Date	Freezed Date
1	02AR21003	Allergic Reactions	General Hospital, Thalasseri	16.06.2021	16.06.2021
2	02AR21004	Allergic Reactions	District Hospital, Thodupuzha, Idukki	10.07.2021	10.07.2021
3	02AR21005	Induration following intradermal test dose (an increase in the fibrous elements in tissue commonly associated with inflammation and marked by loss of elasticity and pliability)	General Hospital, Thalasseri	19.06.2021	19.06.2021
4	02AR21005	Allergic Reactions	General Hospital, Thalasseri	03.11.2021	05.11.2021
5	02AR21004	Itching, Swelling and redness at the site of administration.	GH Kalpetta, Wayanad	23.11.2021	24.11.2021
6	02AR21003	Allergic Reactions	District Hospital, Thodupuzha, Idukki	13.12.2021	13.12.2021
7	02AR22004	Bronchospasm, Urticaria, Itching, Facial oedema.	DH, Kanhangad, Kasaragod	08.05.2022	07.05.2022

  
Dr. SRIRAM VENKATARAMAN IAS  
Managing Director,  
Kerala Medical Services Corporation Ltd.

  
Dr. RAJAN N. KHOBRAGADE IAS  
Chairman, KMSCL &  
Principal Secretary to Government,  
Health & Family Welfare Department.

(AS)

KERALA MEDICAL SERVICES CORPORATION LIMITED  
(Dept. of Health & Family Welfare, Govt of Kerala)  
Thycaud P.O., Thiruvananthapuram - 14,  
Tele Fax No : 0471-2945647, 0471-2945600.  
Website: www.kmscl.kerala.gov.in

Essential Drugs Division

Date : 09-Mar-2023

THE KARUNYA COMMUNITY PHARMACY  
Kerala Medical Services Corporation Ltd,  
Thycaud PO,  
Trivandrum-14

PURCHASE ORDER NO - KMSCL/D-1/KCP/00007/23-24

Ref: 1) Your office email dtd. 24.01.2023 for the procurement of Drugs for the year 23-24

We are pleased to place order for the supply of following item as per the quantity, rate and order value mentioned here in

I. Item Description :-

Drug Code	Drug Name	Min. Shelf Life Required (in months)	Rate per Unit (₹)	Order Quantity (in Units)	Order Value (₹)
D25043	Bleaching Powder (IS-1065), Minimum strength of available Chlorine is 32%, 1 kg Packet	24 ✓	47.0820 ✓	3,49,300	1,64,45,742.60

*1) Packet  
supply direct warehouse*

II. Quantity to be supplied:-

Warehouse Code	District Warehouse Name	Quantity (in units)
01	THIRUVANANTHAPURAM	40,700
02	KOLLAM	30,000
03	PATHANAMTHITTA	29,400
04	ALAPUZHA	35,500
05	KOTTAYAM	30,400
06	IDUKKI	9,300
07	ERNAKULAM	24,900
08	THRISSUR	33,400
09	MALAPPURAM - TIRUR	11,400
10	PALAKKAD	17,700
11	KOZHICKODE	39,100
12	WAYANAD	7,400
13	KANNUR	22,900
14	KASARGODE	6,800
18	MALAPPURAM 2 - MANJERI	10,400
Total Quantity		3,49,300


III. Terms & Conditions:-

- 1) The 100% of above ordered quantity shall be supplied to the warehouses mentioned in Annexure I within 30 days from the date of purchase order.
- 2) The labeled shelf life of drugs supplied should be not less than the period mentioned against the item in the Purchase Order. All items supplied should have minimum 60% shelf life from the date of manufacture when supplied to the Corporation.
- 3) The item supplied should retain prescribed Quality & maximum potency throughout the shelf life.
- 4) All bills/invoices should be raised in duplicate in the name of the Manager, District Drug Warehouse, KMSCL of the respective districts. The original invoice shall be submitted to the IT division at the KMSCL Headquarters for payment process. The duplicate invoice shall be submitted at the District Drug Warehouses/scheduled delivery points along with the supply. Separate invoices should be sent for each consignment.

MANAGING DIRECTOR

Approved for issue

General Manager



# KERALA MEDICAL SERVICES CORPORATION.LTD

(Dept. of Health & Family Welfare Govt. of Kerala)

Thycaud P.O

Thiruvananthapuram-14

Tele Fax No : 0471-2945647 , Tel : 0471-2945667/68

Email id : KCPPURCHASE@KMSCL.KERALA.GOV.IN

40

DL No.: KL-TSR-139473,139475

Tin No.: 32010101829

DL No.: KL-TSR-139474,139476

Community Pharmacy services

Order No.: PROR00000008923 Generated By Reorder Level Process

Date: 18/03/2023

SCHEME.: EDL-N

## LETTER OF INTENT (LOI)

Draft Copy

MANAGING DIRECTOR

M/s. PARKINS ENTERPRISES ( GENERAL / SURGICAL )

Sir,

Sub: KMSCL - LOI for the products under Community Pharmacy Services - reg:-

You are requested to supply the items enclosed as at the below mentioned address immediately ( Annexure 1 includes 1 Items).

KARUNYA MEDICINE DEPOT  
26/736, GENERAL HOSPITAL COMPOUND  
ROUND EAST, THRISSUR  
TAL. THRISSUR ( THRISSUR )  
PIN: 680001

Fax: LST

### Terms & Conditions

- \* The items should be supplied immediately. Original invoice with seal & sign to be submitted at Head Office. Duplicate & triplicate invoices to be submitted at Karunya Depots along with consignment.
- \* All items should have minimum 60% shelf life
- \* The Company/ supplier fails to supply purchase orders within 60 days will be cancelled automatically: In such cases the supplier can be taken an approval through email before executing the PO's.
- \* The items must be supplied as Door Delivery, will not be accepted with LR/RR. LOI number & date should be mentioned in all invoices.
- \* Payment shall be made within 45 days (from the date of receipt of goods at the Warehouse) against invoice by RTGS/NEFT only.
- \* In case of non moving products the supplier shall take back items within 90 days and has to be replaced with other fast moving items.

Other terms & conditions, if any, attached as Annexure I

\* The soft copy of invoices to be send to the Head Office by email (kcppurchase@kmscl.kerala.gov.in ) as scanned copy followed by the original in sealed covers and sent to the following address.

The Deputy Manager ( Karunya Community Pharmacy Procurement Division)  
Kerala Medical Service Corporation (KMSCL) Head Office  
Thycaud, Thiruvananthapuram : 695014  
Telephone: 0471-3045666



MANAGING DIRECTOR

Approved for Issue

GM

General Manager

SCHEME: EDL-N

Order No. PROR00000008923

Draft Copy  
Letter of Intent

Annexure 1


Date: 18/03/2023

M/s.PARKINS ENTERPRISES ( GENERAL / SURGICAL )

SL#	Product	Unit Type	Quantity	Remarks
1	BLEACHING POWDER 30% 1 KG PKT ( CAUVERY ) - PARKINS	NUMBER	349,300	RATE -RS 47.082/UNIT (INCL.GST) MINIMUM SHELF LIFE REQUIRED -24 MONTHS
2	ECG GEL 250GM BOTTLE (ASSOCIATED) - PARKINS - ED	NUMBER	12,700	RATE -20.1488/UNIT (INCL.GST) MINIMUM SHELF LIFE REQUIRED -36 MONTHS

MANAGING DIRECTOR

Approved for Issue

  
GM

General Manager

Entered by  
Pharmacist  
SJK  
20/03/2023

